Almac Group Concludes Commercial API Manufacturing Facility Expansion Plans
Published: Oct 09, 2012
Almac’s strategy to increase market share in late phase clinical development is reaping rewards, and clients are already seeing the advantages of having one constant manufacturing partner through each phase of clinical development. “Almac’s investment has further demonstrated our goal of being the outsourcing partner of choice through all stages of clinical development.” stated Denis Geffroy, VP Business Development. “We are delighted to have the scale to share the manufacturing journey with our clients from preclinical phase to full commercialisation.”
Clients can also leverage Almac’s API and Drug Product integrated offering where API manufacture and finished drug production is carried out on the same site, ensuring reduction in costs and timelines whilst maintaining scientific continuity. Almac’s advantage of hosting all facilities on one site have led to the successful technology transfer of small molecule and peptide projects from lab development to large scale manufacture.
For further information, Almac will be exhibiting at the forthcoming CPhI (Booth 10E41) and AAPS (Booth 3027) conferences.
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has now moved into its new North American Headquarters located in Souderton PA.